Side-by-side · Research reference

SelankvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft11/40 cited

BFDA-ApprovedVerified14/45 cited

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Selank

Tirzepatide

Primary target

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

No GABA-receptor binding; no dependence reportedMedvedev 2007

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Selank

Tirzepatide

Standard dose

150–300 mcg / dose intranasalZaderej 2014

—

Frequency

2–3× per day during stress

—

Lower / starter dose

75 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinical trialsMedvedev 2007

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Duration

10–14 day cycles, repeated as needed

Indefinite for chronic indication

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

Morning + early afternoon preferred

Once weekly, any time of day

Half-life

Short (minutes plasma); CNS effect lasts ~3 hr

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter

Selank

Tirzepatide

Nasal irritation

Mild burning or congestion (transient)

—

Sedation

None — distinct from benzodiazepinesMedvedev 2007

—

Dependence / withdrawal

None reported in clinical useZaderej 2014

—

Cognitive impairment

None — opposite effect (enhancement)

—

Allergic reaction

Rare hypersensitivity

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid — insufficient data

Contraindicated

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Selank

·Active autoimmune disease (theoretical via immunomodulation)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Selank

Tirzepatide

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Administration

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Refrigerate after reconstitution; ≤30 days. Light-protected.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Caveat

Avoid co-administration with strong sedatives or other anxiolytics initially.

Pen-supplied. Research vial: 27–31G insulin syringe.